Refoxy Pharmaceuticals GmbH - Activating Healthy Aging

Science

Company

Team

News

Contact

Science

Company

Team

News

Contact

Reimagining Healthy Aging

At Refoxy, we’re developing next-generation medicines to treat age-related diseases and extend the number of years people can live in good health. Our work targets FOXO3, a master regulator of cellular resilience, to unlock better outcomes for patients facing some of today’s most challenging chronic conditions.

Learn more

Our Investors

Repair. Restore. Rejuvenate

We create advanced biotechnologies that combat age-related diseases, enhancing health and extending quality of life by addressing aging at its core.

How We Do It

Activating Cellular Health at Its Core

Modulating FOXO3 offers a powerful strategy for treating age-related diseases due to its central role in maintaining cellular balance and coordinating the body’s response to stress across multiple organs. While traditional drug development often targets isolated proteins or pathways, FOXO3 functions as a master regulator, influencing a wide range of biological processes. By activating this key transcription factor, we aim to deliver more effective treatments for complex, multifactorial conditions such as fibrotic and cardiovascular diseases, ultimately improving health span and resilience with age.

While traditional drug development often targets isolated proteins or pathways, FOXO3 functions as a master regulator, influencing a wide range of biological processes.

By activating this key transcription factor, we aim to deliver more effective treatments for complex, multifactorial conditions such as fibrotic and cardiovascular diseases, ultimately improving health span and resilience with age.

Learn more

What we do

Creating Novel Therapies for Age-Related Diseases

At Refoxy, we develop innovative medicines to treat age-related conditions by enhancing the body’s natural ability to resist cellular stress and damage. Our work focuses on diseases like Idiopathic Pulmonary Fibrosis (IPF), targeting the root causes of aging to extend healthy living.

Company

meet our team

Refoxy is led by a team of scientists, entrepreneurs, and biotech innovators who share a common belief: that aging biology holds the key to solving some of medicine’s toughest challenges. From the lab to the boardroom, we are committed to advancing science that makes a real difference in people’s lives.

Our lead series has shown robust anti-fibrotic effects in preclinical studies and is currently being developed for Idiopathic Pulmonary Fibrosis (IPF) — a severe, life-limiting lung disease. This program is just the beginning.

We are also advancing a broader pipeline of FOXO3-targeting molecules for additional indications where aging and chronic stress are key drivers of pathology.